192 related articles for article (PubMed ID: 23603069)
1. Enzyme replacement therapy and fatigue in adults with Pompe disease.
Güngör D; de Vries JM; Brusse E; Kruijshaar ME; Hop WC; Murawska M; van den Berg LE; Reuser AJ; van Doorn PA; Hagemans ML; Plug I; van der Ploeg AT
Mol Genet Metab; 2013 Jun; 109(2):174-8. PubMed ID: 23603069
[TBL] [Abstract][Full Text] [Related]
2. Long-term benefit of enzyme replacement therapy in Pompe disease: A 5-year prospective study.
Kuperus E; Kruijshaar ME; Wens SCA; de Vries JM; Favejee MM; van der Meijden JC; Rizopoulos D; Brusse E; van Doorn PA; van der Ploeg AT; van der Beek NAME
Neurology; 2017 Dec; 89(23):2365-2373. PubMed ID: 29117951
[TBL] [Abstract][Full Text] [Related]
3. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease.
Nilsson MI; Samjoo IA; Hettinga BP; Koeberl DD; Zhang H; Hawke TJ; Nissar AA; Ali T; Brandt L; Ansari MU; Hazari H; Patel N; Amon J; Tarnopolsky MA
Mol Genet Metab; 2012 Nov; 107(3):469-79. PubMed ID: 23041258
[TBL] [Abstract][Full Text] [Related]
4. Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease.
Harlaar L; Hogrel JY; Perniconi B; Kruijshaar ME; Rizopoulos D; Taouagh N; Canal A; Brusse E; van Doorn PA; van der Ploeg AT; Laforêt P; van der Beek NAME
Neurology; 2019 Nov; 93(19):e1756-e1767. PubMed ID: 31619483
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy.
van der Meijden JC; Kruijshaar ME; Harlaar L; Rizopoulos D; van der Beek NAME; van der Ploeg AT
J Inherit Metab Dis; 2018 Nov; 41(6):1205-1214. PubMed ID: 29556838
[TBL] [Abstract][Full Text] [Related]
6. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
Kishnani PS; Beckemeyer AA
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case.
Kobayashi H; Shimada Y; Ikegami M; Kawai T; Sakurai K; Urashima T; Ijima M; Fujiwara M; Kaneshiro E; Ohashi T; Eto Y; Ishigaki K; Osawa M; Kyosen SO; Ida H
Mol Genet Metab; 2010 May; 100(1):14-9. PubMed ID: 20202878
[TBL] [Abstract][Full Text] [Related]
8. Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis.
Hundsberger T; Rösler KM; Findling O
J Neurol; 2014 Sep; 261(9):1684-90. PubMed ID: 24923245
[TBL] [Abstract][Full Text] [Related]
9. Sixty six-month follow-up of muscle power and respiratory function in a case with adult-type Pompe disease treated with enzyme replacement therapy.
Isayama R; Shiga K; Seo K; Azuma Y; Araki Y; Hamano A; Takezawa H; Kuriyama N; Takezawa N; Mizuno T; Nakagawa M
J Clin Neuromuscul Dis; 2014 Jun; 15(4):152-6. PubMed ID: 24872213
[TBL] [Abstract][Full Text] [Related]
10. Effects of exercise training during infusion on late-onset Pompe disease patients receiving enzyme replacement therapy.
Terzis G; Krase A; Papadimas G; Papadopoulos C; Kavouras SA; Manta P
Mol Genet Metab; 2012 Dec; 107(4):669-73. PubMed ID: 23146291
[TBL] [Abstract][Full Text] [Related]
11. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa.
de Vries JM; van der Beek NA; Kroos MA; Ozkan L; van Doorn PA; Richards SM; Sung CC; Brugma JD; Zandbergen AA; van der Ploeg AT; Reuser AJ
Mol Genet Metab; 2010 Dec; 101(4):338-45. PubMed ID: 20826098
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease.
Kanters TA; van der Ploeg AT; Kruijshaar ME; Rizopoulos D; Redekop WK; Rutten-van Mӧlken MPMH; Hakkaart-van Roijen L
Orphanet J Rare Dis; 2017 Dec; 12(1):179. PubMed ID: 29237491
[TBL] [Abstract][Full Text] [Related]
13. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
[TBL] [Abstract][Full Text] [Related]
14. Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study.
de Vries JM; van der Beek NA; Hop WC; Karstens FP; Wokke JH; de Visser M; van Engelen BG; Kuks JB; van der Kooi AJ; Notermans NC; Faber CG; Verschuuren JJ; Kruijshaar ME; Reuser AJ; van Doorn PA; van der Ploeg AT
Orphanet J Rare Dis; 2012 Sep; 7():73. PubMed ID: 23013746
[TBL] [Abstract][Full Text] [Related]
15. 24-months results in two adults with Pompe disease on enzyme replacement therapy.
Vielhaber S; Brejova A; Debska-Vielhaber G; Kaufmann J; Feistner H; Schoenfeld MA; Awiszus F
Clin Neurol Neurosurg; 2011 Jun; 113(5):350-7. PubMed ID: 21477922
[TBL] [Abstract][Full Text] [Related]
16. 36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe Registry.
Scheidegger O; Leupold D; Sauter R; Findling O; Rösler KM; Hundsberger T
J Neurol; 2018 Dec; 265(12):2783-2788. PubMed ID: 30232608
[TBL] [Abstract][Full Text] [Related]
17. Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme®) in 12 patients with advanced late-onset Pompe disease.
Papadopoulos C; Orlikowski D; Prigent H; Lacour A; Tard C; Furby A; Praline J; Solé G; Hogrel JY; De Antonio M; Semplicini C; Deibener-Kaminsky J; Kaminsky P; Eymard B; Taouagh N; Perniconi B; Hamroun D; Laforêt P;
Mol Genet Metab; 2017 Sep; 122(1-2):80-85. PubMed ID: 28648663
[TBL] [Abstract][Full Text] [Related]
18. Effect of enzyme replacement therapy on isokinetic strength for all major muscle groups in four patients with Pompe disease-a long-term follow-up.
Andreassen CS; Schlütter JM; Vissing J; Andersen H
Mol Genet Metab; 2014 May; 112(1):40-3. PubMed ID: 24685124
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS
Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983
[TBL] [Abstract][Full Text] [Related]
20. Adult Pompe disease: clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy.
Papadimas GK; Spengos K; Konstantinopoulou A; Vassilopoulou S; Vontzalidis A; Papadopoulos C; Michelakakis H; Manta P
Clin Neurol Neurosurg; 2011 May; 113(4):303-7. PubMed ID: 21216089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
